

CAMSON BIO TECHNOLOGIES LIMITED  
STATEMENT OF AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MAR 2015

Sl. No.	Particulars	Standalone								Rupees in Lakhs
		Quarter Ended		Year Ended		Year Ended		Previous Year Ended		
		31st Mar 2015 (Audited)	31st Dec 2014 (Unaudited)	31st Mar 2014 (Audited)	31st Mar 2015 (Audited)	31st Mar 2014 (Audited)	31st Mar 2014 (Audited)	31st Mar 2014 (Audited)	31st Mar 2014 (Audited)	
1	Income from Operations	3,749.69	5,458.51	3,910.98	16,938.15	14,562.78	14,562.78	14,562.78		
	(a) Net sales / income from Operations (Net of Excise duty)									
	(b) Other Operating Income									
	<b>Total Income from Operations (net)</b>	<b>3,749.69</b>	<b>5,458.51</b>	<b>3,910.98</b>	<b>16,938.15</b>	<b>14,562.78</b>	<b>14,562.78</b>	<b>14,562.78</b>		
2	Expenses									
	(a) Cost of Materials consumed	308.03	690.52	462.67	3,412.41	2,131.52	2,131.52	2,131.52		
	(b) Purchase of stock-in-trade	492.43	165.00	2,298.28	2,596.99	4,866.83	4,866.83	4,866.83		
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,452.98	1,729.55	(1,050.69)	1,634.09	(291.73)	(291.73)	(291.73)		
	(d) Employee benefits expense	337.64	344.72	255.77	1,293.52	856.76	856.76	856.76		
	(e) Depreciation and amortisation expense	334.75	335.51	134.58	1,340.28	311.30	311.30	311.30		
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)									
i	Geo- Climatic Trials	258.64	136.47	111.65	724.34	410.59	410.59	410.59		
ii	Selling and Promotion Expenses	372.43	1,212.01	391.16	2,553.47	1,931.16	1,931.16	1,931.16		
iii	Other Expenses	853.56	424.32	322.01	3,104.75	2,189.45	2,189.45	2,189.45		
	<b>Total Expenses</b>	<b>4,405.46</b>	<b>5,038.10</b>	<b>3,125.53</b>	<b>16,659.85</b>	<b>12,605.88</b>	<b>12,605.88</b>	<b>12,605.88</b>		
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(655.77)	420.41	785.35	278.30	1,956.90	1,956.90	1,956.90		
4	Other Income	388.39	32.34	4.77	635.22	53.28	53.28	53.28		
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(267.38)	452.75	789.62	913.52	2,010.18	2,010.18	2,010.18		
6	Finance Cost	161.21	73.04	121.42	408.73	386.86	386.86	386.86		
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	(428.59)	379.71	668.20	504.79	1,623.32	1,623.32	1,623.32		
8	Exceptional Items					356.30	356.30	356.30		
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	(428.59)	379.71	668.20	504.79	1,623.32	1,623.32	1,623.32		
10	Tax Expense	85.68	184.18	(147.66)	196.56	(60.10)	(60.10)	(60.10)		
11	Net Profit / (Loss) from Ordinary Activities after tax (9 + 10)	(342.91)	563.89	815.86	308.23	1,327.12	1,327.12	1,327.12		
12	Extraordinary Items (net of tax expenses)									
13	Net Profit / (Loss) for the period (11 + 12)	(342.91)	563.89	815.86	308.23	1,327.12	1,327.12	1,327.12		
14	Share of Profit / (Loss) of associates									
15	Minority Interest									
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15)	(342.91)	563.89	815.86	308.23	1,327.12	1,327.12	1,327.12		
17	Paid up Equity Share Capital (Face value of the Share is Rs. 10/-)	2,999.98	2,999.98	2,527.55	2,999.98	2,527.55	2,527.55	2,527.55		
18	Reserves excluding Revaluation Reserve as per Balance Sheet of the Previous Accounting Year				23,398.49	17,863.38	17,863.38	17,863.38		
19.i	Earning per share (before extraordinary items) (of Rs.10 /- each) (not annualised): Rs									
	(a) Basic	(1.10)	0.65	3.23	1.07	5.65	5.65	5.65		
	(b) diluted	(1.10)	0.65	2.72	1.07	4.72	4.72	4.72		
19.ii	Earning per share (after extraordinary items) (of Rs.10 /- each) (not annualised): Rs									
	(a) Basic	(1.10)	0.65	3.23	1.07	5.65	5.65	5.65		
	(b) diluted	(1.10)	0.65	2.72	1.07	4.72	4.72	4.72		

Handwritten initials and a signature.

CAMSON BIO TECHNOLOGIES LIMITED  
PART II - SELECT INFORMATION FOR THE QUARTER AND YEAR ENDED AS ON 31ST MAR 2015

Sl. No.	Particulars	Stantalone						
		Quarter Ended		Year Ended		Previous Year Ended		
		31st Mar 2015 (Audited)	31st Dec 2014 (Unaudited)	31st Mar 2014 (Audited)	31st Mar 2015 (Audited)	31st Mar 2014 (Audited)	31st Mar 2014 (Audited)	
A	<b>PARTICULARS OF SHAREHOLDING</b>							
1	Public Shareholding	2,26,61,240	2,26,61,240	1,85,86,913	2,26,61,240	1,85,86,913	1,85,86,913	
	- Number of Shares *	75.54%	75.54%	73.68%	75.54%	73.68%	73.68%	
2	Promoters and Promoter group shareholding							
a)	Pledged/Encumbered - Number of Shares	0%	0%	0%	0%	0%	0%	0%
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0%	0%	0%	0%	0%	0%	0%
	Percentage of shares (as a % of the total share capital of the company)	0%	0%	0%	0%	0%	0%	0%
b)	Non-encumbered							
	Number of shares	73,38,600	73,38,600	66,38,600	73,38,600	66,38,600	66,38,600	
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%	
	Percentage of Shares (as a % of the total share Capital of the Company)	24.45%	24.45%	26.32%	24.46%	26.32%	26.32%	

B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during this quarter	Nil
	Remaining unresolved at the end of the quarter	Nil

W AX J

**CAWSON BIO TECHNOLOGIES LIMITED**  
**REPORT OF SEGMENT-WISE CONSOLIDATED REVENUE, RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE 61 OF THE LISTING AGREEMENT FOR QUARTER AND YEAR ENDED AS ON 31ST MAR 2015**

Sl. No.	Particulars	Standalone						Previous Year Ended 31st Mar 2014 (Audited)
		Quarter Ended		Year Ended		31st Mar 2014 (Audited)		
		31st Mar 2015 (Audited)	31st Dec 2014 (Unaudited)	31st Mar 2015 (Audited)	31st Mar 2014 (Audited)			
1	<b>Segment Revenue</b>							
	a) Seeds	3,043.75	3,398.48	3,159.33	10,943.05	10,260.12	10,260.12	
	b) Agri biotech Products	705.84	2,060.03	751.65	5,995.10	4,302.66	4,302.66	
	c) Others	-	-	-	-	-	-	
	<b>Total</b>	<b>3,749.69</b>	<b>5,458.51</b>	<b>3,910.98</b>	<b>16,938.15</b>	<b>14,562.78</b>	<b>14,562.78</b>	
	Less: Intersegment Revenue	-	-	-	-	-	-	
	<b>Net Sales/ Income from Operation</b>	<b>3,749.69</b>	<b>5,458.51</b>	<b>3,910.98</b>	<b>16,938.15</b>	<b>14,562.78</b>	<b>14,562.78</b>	
2	<b>Segment Results</b>							
	<b>Profit (+) / Loss (-) before tax and interest from each segment</b>							
	a) Seeds	565.05	325.41	1,167.46	1,384.80	2,058.95	2,058.95	
	b) Agri biotech Products	(301.62)	352.57	(80.71)	511.96	443.53	443.53	
	c) Others	-	-	-	-	-	-	
	<b>Total</b>	<b>263.43</b>	<b>677.98</b>	<b>1,086.75</b>	<b>1,906.76</b>	<b>2,502.48</b>	<b>2,502.48</b>	
	Less: (i) Other Net unallocated Income / expenses	330.61	225.23	297.13	993.24	848.60	848.60	
	(ii) Finance Cost	161.21	73.04	121.42	408.73	386.86	386.86	
	<b>Total Profit before Tax</b>	<b>(228.59)</b>	<b>379.71</b>	<b>668.20</b>	<b>504.79</b>	<b>1,267.02</b>	<b>1,267.02</b>	
3	<b>Capital Employed</b>							
	[Segment Assets-Segment Liabilities]							
	a) Seeds	14,254.81	13,291.38	12,908.54	14,254.81	12,908.54	12,908.54	
	b) Agri Biotech products	9,025.30	9,544.85	8,693.73	9,025.30	8,693.73	8,693.73	
	c) Others	3,118.36	3,348.95	1,154.69	3,118.36	1,154.69	1,154.69	
	<b>TOTAL</b>	<b>26,398.47</b>	<b>26,285.18</b>	<b>22,696.96</b>	<b>26,398.47</b>	<b>22,696.96</b>	<b>22,696.96</b>	


CAMSON BIO TECHNOLOGIES LIMITED

STATEMENT OF ASSETS AND LIABILITIES UNDER CLAUSE 41(V) OF THE LISTING AGREEMENT

Sl. No	PARTICULARS	Rupees in Lakhs	
		Standalone As at 31-Mar-15 {Audited}	As at 31-Mar-14 {Audited}
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
1	<b>Shareholders' Funds</b>		
	(a) Share Capital	2,999.58	2,522.55
	(b) Reserves and Surplus	23,398.49	17,863.38
	(c) Money Received Against Share Warrants	-	2,311.04
	<b>Sub Total - Shareholders Funds</b>	<b>26,398.47</b>	<b>24,696.97</b>
	Minority Interest	-	-
2	<b>Non-Current Liabilities</b>		
	(a) Long Term Borrowings	494.14	1,194.55
	(b) Other Long term Liabilities	244.97	191.74
	(c) Deferred Tax Liabilities (Net)	177.97	-
	(d) Long Term Provisions	88.31	53.03
	<b>Sub Total - Non Current liabilities</b>	<b>1,005.39</b>	<b>1,439.32</b>
3	<b>Current Liabilities</b>		
	(a) Short Term Borrowings	3,168.94	2,512.38
	(b) Trade Payables	1,037.15	351.85
	(c) Other Current Liabilities	469.43	883.76
	(d) Short Term Provisions	284.14	351.33
	<b>Sub Total - Current Liabilities</b>	<b>4,960.66</b>	<b>4,099.32</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>32,364.52</b>	<b>28,235.61</b>
<b>B</b>	<b>ASSETS</b>		
1	<b>Non-Current Assets</b>		
	(a) Fixed Assets		
	(i) Tangible Assets	11,110.90	7,754.68
	(ii) Intangible Assets	2,743.77	3,205.69
	(iii) work in progress	-	0.99
	(b) Intangible Asset under Development	-	-
	(c) Good will on consolidation	-	-
	(d) Non-Current Investments	0.83	0.83
	(e) Deferred Tax Asset (Net)	-	9.67
	(f) Long Term Loans & Advances	768.48	3,881.78
	<b>Sub Total - Non-Current Assets</b>	<b>14,623.98</b>	<b>14,853.64</b>
2	<b>Current Assets</b>		
	(a) Inventories	2,533.60	3,957.67
	(b) Trade Receivables	14,548.65	8,401.44
	(c) Cash & Cash Equivalents	102.90	191.83
	(d) Short Term Loans & Advances	555.41	791.03
	(e) Other Current Assets	-	-
	<b>Sub Total - Current Assets</b>	<b>17,740.54</b>	<b>13,361.97</b>
	<b>TOTAL ASSETS</b>	<b>32,364.52</b>	<b>28,235.61</b>

11/11/15

**CAMSON BIO TECHNOLOGIES LIMITED**

Notes :

- The above Financial Results were reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at its meeting held on 19th May 2015.
- The nature of the Company's business being related to agriculture and the composition of income varying due to the underlying environmental and market conditions, the results of the company quarter on quarter can vary significantly and are therefore not comparable.
- The Company has revised depreciation rates on fixed assets effective April 1, 2014 in accordance with requirement of schedule II of Companies Act 2013 ("the Act"). The remaining useful life has been revised by adopting standard useful life as per the Companies Act, 2013. Consequently upon such change the depreciation amounting to Rs.90.78 lakhs (net of deferred tax of Rs. 8.91 lakhs) has been adjusted against reserves in respect of assets which have already completed their useful lives before April 2014 and for other assets depreciation has been charged based on their remaining useful life. Had the company continued with the previously assessed useful lives, the charge for depreciation would have been lower by Rs.93.77 lakhs and Rs.353 lakhs for the quarter and year ended 31st Mar 2015 respectively.
- The Management of the Company intended to demerge its seeds division to Camson Seeds Limited through Court approved Scheme of Arrangement. In this process, the Management has conducted and obtained approval in the Court Convened Meetings of shareholders and creditors on April 23, 2015 and complied with the directions of High Court as per dated 26<sup>th</sup> March, 2015. The Company has filed the voting results and outcome of the meeting with Stock Exchange (SE). The Company has filed the Petition vide no 105/2015 with Honbl. High Court of Karnataka and awaiting Approval". On approval of the Scheme by the Honourable High Court, shareholders of Camson Bio Technologies Limited will get one equity share of Camson Seeds Limited for every share held in Camson Bio Technologies Limited.

Financial results of discontinuing operation, subject to approval of the scheme by the Honourable High Court, under Accounting Standard 24 are given below :-

PARTICULARS	2014-15	2013-14
REVENUE	1,09,58,94,512	1,02,60,12,151
EMPLOYEE BENEFIT COST	3,51,57,256	2,91,03,989
DEPRECIATION	5,53,72,217	2,98,80,680
FINANCE COST	2,64,06,141	2,72,56,109
OTHER EXPENSES	28,45,24,958	16,22,98,560
<b>NET PROFIT</b>	<b>13,94,79,190</b>	<b>11,89,51,644</b>

- The Company has formulated Employee Stock Option plan 2012, drafted in accordance with the SEBI (Employee Stock Option Scheme) Guidelines, 1999. The Company has granted 14,99,990 stock options to their eligible employees in its board meeting held on Dt: Feb 12, 2015, to acquire equity shares of the Company which vest in a graded manner and to be exercised within a specified period. In accordance with the SEBI Guidelines; the excess of Rs. 0.50/- on the closing market price of Rs. 109.5/-, the day prior to the grant of the options under ESOS over the exercise price of Rs. 109/- is amortized on a straight-line basis over the vesting period. (Amortisation amount - Rs. 32876/-)

As per the Scheme, the Remuneration / Compensation Committee granted the options to the employees deemed eligible. The exercise price of each option is Rs 109. The Vesting period of the options shall be as follows:

After the date of Grant, upon the expiry of	% of options which would vest
12 months	33.34% of options
24 months	33.33% of options
36 months	33.33% of options

- The Company operates in two segments i.e. Seeds and Agribiotech products.
- The figures of last quarter are the balancing figures between audited figures in respect of full financial year and the published year to third quarter of current financial year. A limited review was carried out on the figures for the quarter ended 31st December, 2014.
- Figures for the previous periods/years have been regrouped/rearranged wherever necessary.

Date :19.05.2015  
Place: Bangalore

For and on behalf of the Board of Directors



DHIRENDRA KUMAR  
Managing Director




## INDEPENDENT AUDITORS' REPORT

To the Members of **CAMSON BIO TECHNOLOGIES LIMITED**

### Report on the Standalone Financial Statements

1. We have audited the accompanying standalone financial statements of Camson Bio Technologies Limited, ("the Company"), which comprise the Balance Sheet as at March 31, 2015, and the Statements of Profit and Loss and Cash Flow for the year then ended, and a summary of the significant accounting policies and other explanatory information.

### Management's Responsibility for the Financial Statements

2. The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended). This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

### Auditor's Responsibility

3. Our responsibility is to express an opinion on these standalone financial statements based on our audit.
4. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.



**Pune**  
T + 91 020 60601005/6/7/8/9  
- 91 020 25666932/32926341  
E bkkpune@bkkhareco.com  
Hotel Swaroop, 4th Floor,  
Lane No.10, Prabhat Road,  
Erandwane, Pune - 411 004, India

**Bengaluru**  
T + 91 80 41105357  
E bkkbengaluru@bkkhareco.com  
101, Money Chambers,  
1st Floor, # 6 K. H. Road,  
Shanthinagar,  
Bengaluru - 560027, India

**New Delhi**  
T + 91 011 4182 8360  
E bkkdelhi@bkkhareco.com  
107, Siddharth Chambers,  
Near IIT Gate,  
Kalu Sarai, Hauz Khas,  
New Delhi - 110 016, India.

5. We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.
6. An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.
7. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

#### Opinion

8. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the state of affairs of the Company as at March 31, 2015, and its loss and cash flows for the year ended on that date.

#### Report on Other Legal and Regulatory Requirements

9. As required by the Companies (Auditor's Report) Order, 2015, issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act (the "Order"), and on the basis of such checks of the books and records of the Company as we considered appropriate and according to the information and explanations given to us, we give in the Annexure a statement on the matters specified in paragraphs 4 and 5 of the Order.



10. As required by Section 143(3) of the Act, we report that:

- a. we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
- b. in our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- c. the Balance Sheet, the Statement of Profit and Loss and Cash Flow dealt with by this Report are in agreement with the books of account;
- d. In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended);
- e. On the basis of written representations received from the directors as on March 31, 2015 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2015, from being appointed as a director in terms of Section 164(2) of the Act.
- f. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us:
  - i. The Company does not have any pending litigations which would impact its financial position.
  - ii. The Company did not have any long-term contracts including derivate contracts for which there were any material foreseeable losses.
  - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For B. K. Khare & Co.  
Chartered Accountants  
Firm's Registration Number 105102W



**Padmini Khare Kaicker**  
Partner  
Membership Number: 044784  
Dated May 19, 2015  
Place, Bangalore





**Annexure to the Independent Auditors' Report**

(Referred to in paragraph 9 under "Report on other legal and regulatory requirements" of our report of even date on the financial statements for the year ended on March 31, 2015 of Camson Bio Technologies Limited)

i. (a) The Company has maintained proper records showing full particulars including quantitative details and situation of fixed assets.

(b) According to information and explanation the fixed assets of the company were physically verified by the management during the year and no material discrepancies were noticed on such verification.

ii. (a) Physical verification of inventory was conducted by the management at reasonable interval during the year.

(b) In our opinion and according to the information and explanations given to us, the procedure of physical verification of stocks followed by the management is reasonable and adequate in relation to the size of the company and nature of its business.

(c) In our opinion and according to the information and explanations given to us, the Company is maintaining proper records of inventory and discrepancies noticed on physical verification by the Management have been properly adjusted in the books of account.

iii. There are no companies, firms or other parties covered in the register maintained under Section 189 of the Act. Therefore, the provisions of Clause 3(iii) of the said order are not applicable to the Company.

iv. In our opinion and according to the information and explanations given to us, there is an adequate internal control system commensurate with the size of the Company and the nature of its business, for the purchase of inventory and fixed assets and for the sale of goods and services. During the course of our audit, we have not observed any major weakness or continuing failure to correct any major weakness in the internal control system of the Company in respect of these areas.

v. In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits from the public within the meaning of Sections 73, 74, 75 and 76 of the Act and rules framed there under to the extent notified. Consequently, no order has been passed by the Company Law Board or National Company Law Commission or Reserve Bank of India or any court or any other tribunal on the Company.



vi. We have broadly reviewed the books of accounts maintained by the Company pursuant to the rules made by the central government for the maintenance of cost records under section 209 1(d) of the companies Act 2013 in respect of fertiliser products and are of the opinion that prima facie the prescribed accounts and records have been made and maintained.

vii. (a) According to information and explanation given to us, and as per our verification of records of the company, the company is regular in depositing with appropriate authorities undisputed statutory dues deducted/accrued in the books of account in respect of provident fund, investor education and protection fund, employees' state insurance, income tax, service tax, sales tax, wealth tax, custom duty, excise duty, cess and other material statutory dues have been regularly deposited with the appropriate authorities.

(b) According to the information and explanations given to us and records of the Company examined by us, there are no dues of income tax, sales tax, wealth tax, service tax, duty of excise, duty of customs, value added tax, and cess which have not been deposited on account of any dispute.

(c) According to information and explanation given to us, there is no amount to be transferred to investor education and protection fund in accordance with relevant provisions of the companies act.

viii. The Company has no accumulated losses at the end of the financial year. The Company has not incurred cash losses in current financial year as well as in the immediately preceding financial year

ix. Based on the records examined by us and according to the information and explanations given to us, the Company has not defaulted in repayment of dues to any financial institution or bank as at the Balance Sheet date.


x. In our opinion and according to the information and explanations given to us, the Company has not granted any loans and advances on the basis of security by way of pledge of shares, debentures and other securities.

xi. According to the information and explanation given to us, term loans have been applied for the purpose for which the loans were obtained.



xii. During the course of our examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practices in India, and according to the information and explanations given to us, we have neither come across any instance of fraud on or by the Company, noticed or reported during the year, nor have we been informed of any such case by the Management.

For B. K. Khare & Co.  
Chartered Accountants  
Firm's Registration Number 105102W



**Padmini Khare Kaicker**  
Partner  
Membership Number: 044784  
Dated May 19, 2015  
Place, Bangalore



**CAMSON BIO TECHNOLOGIES LIMITED**  
**STATEMENT OF AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MAR 2015**

Sl. No.	Particulars	Consolidated						Rupees in Lakhs
		Quarter Ended		Year Ended		Previous Year Ended		
		31st Mar 2015 (Audited)	31st Dec 2014 (Unaudited)	31st Mar 2014 (Audited)	31st Mar 2015 (Audited)	31st Mar 2014 (Audited)	31st Mar 2014 (Audited)	
1	Income from Operations (a) Net sales / income from Operations (Net of Excise duty)	4,616.79	6,351.15	3,949.25	20,302.02	19,089.16	19,089.16	
	(b) Other Operating Income	-	-	-	-	-	-	
2	Total Income from Operations (net)	4,616.79	6,351.15	3,949.25	20,302.02	19,089.16	19,089.16	
	(a) Cost of Materials consumed	536.57	765.65	443.66	3,716.18	2,104.56	2,104.56	
	(b) Purchase of stock-in-trade	1,083.80	874.80	2,367.50	5,407.79	9,320.98	9,320.98	
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,360.68	1,715.24	(1,094.52)	1,543.12	(332.76)	(332.76)	
	(d) Employee benefits expense	458.12	412.61	271.63	1,530.40	935.16	935.16	
	(e) Depreciation and amortisation expense	378.77	350.73	134.62	1,399.67	511.37	511.37	
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	-	-	-	-	-	-	
	i Geo - Climatic Trials	258.64	136.47	111.65	724.34	470.59	470.59	
	ii Selling and Promotion Expenses	375.60	1,212.34	391.52	2,550.31	1,933.25	1,933.25	
	iii Other Expenses	1,011.76	461.68	584.73	3,354.27	2,746.44	2,746.44	
3	Total Expenses	5,463.94	5,949.53	3,164.19	20,226.08	17,129.59	17,129.59	
	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(847.15)	401.62	785.06	75.94	1,959.57	1,959.57	
4	Other income	590.47	35.15	4.31	542.27	53.32	53.32	
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(256.68)	436.77	789.37	718.21	2,012.89	2,012.89	
6	Finance Cost	207.88	102.06	172.14	509.13	387.59	387.59	
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	(464.56)	334.71	617.23	209.08	1,625.30	1,625.30	
8	Exceptional items	-	-	-	-	356.30	356.30	
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	(464.56)	334.71	617.23	209.08	1,269.00	1,269.00	
10	Tax Expense	37.19	189.91	(136.35)	197.87	(47.90)	(47.90)	
11	Net Profit / (Loss) from Ordinary Activities after tax (9 + 10)	(551.75)	144.80	803.58	11.21	1,316.90	1,316.90	
12	Extraordinary items (net of tax expenses)	-	-	-	-	-	-	
13	Net Profit / (Loss) for the period (11 + 12)	(551.75)	144.80	803.58	11.21	1,316.90	1,316.90	
14	Share of Profit / (Loss) of associates	(146.21)	(30.26)	(1.59)	(182.33)	(0.88)	(0.88)	
15	Minority Interest	-	-	-	-	-	-	
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15)	(405.54)	175.06	805.17	199.53	1,317.78	1,317.78	
17	Paid up Equity Share Capital (Face value of the Share is Rs. 10/-)	2,999.86	2,999.96	2,527.55	2,999.88	2,527.55	2,527.55	
18	Reserves excluding Revaluation Reserve as per Balance Sheet of the Previous Accounting Year	-	-	-	23,324.65	17,904.22	17,904.22	
19	Earning per share (before extraordinary items) (of Rs.10 /- each) (not annualised): Rs	(1.41)	0.58	3.19	0.67	5.61	5.61	
	(a) Basic	(1.41)	0.58	3.19	0.67	5.61	5.61	
	(b) diluted	(1.41)	0.58	3.19	0.67	5.61	5.61	
19.iii	Earning per share (after extraordinary items) (of Rs.10 /- each) (not annualised): Rs	(1.41)	0.58	3.19	0.67	5.61	5.61	
	(a) Basic	(1.41)	0.58	3.19	0.67	5.61	5.61	
	(b) diluted	(1.41)	0.58	3.19	0.67	5.61	5.61	


CAMSON BIO TECHNOLOGIES LIMITED  
PART II SELECT INFORMATION FOR THE QUARTER AND YEAR ENDED AS ON 31ST MAR 2015

Sl. No.	Particulars	Consolidated							
		Quarter Ended		Year Ended		Year Ended		Previous Year Ended	
		31st Mar 2015 (Audited)	31st Dec 2014 (Unaudited)	31st Mar 2014 (Audited)	31st Mar 2015 (Audited)	31st Mar 2014 (Audited)	31st Mar 2014 (Audited)	31st Mar 2014 (Audited)	31st Mar 2014 (Audited)
A	<b>PARTICULARS OF SHAREHOLDING</b>								
1	Public Shareholding	2,26,61,240	2,26,61,240	1,85,86,913	2,26,61,240	1,85,86,913	1,85,86,913	1,85,86,913	73.68%
	- Number of Shares *	75.54%	75.54%	73.68%	75.54%	73.68%	73.68%	73.68%	73.68%
	- Percentage of Shareholding								
2	<b>Promoters and Promoter group shareholding</b>								
a)	Pledged/Encumbered - Number of Shares	0%	0%	0%	0%	0%	0%	0%	0%
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0%	0%	0%	0%	0%	0%	0%	0%
	Percentage of shares (as a % of the total share capital of the company)	0%	0%	0%	0%	0%	0%	0%	0%
b)	<b>Non-encumbered</b>								
	Number of shares	73,38,600	73,38,600	86,38,600	73,38,600	86,38,600	66,38,600	66,38,600	100%
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%	100%	100%
	Percentage of Shares (as a % of the total share Capital of the Company)	24.46%	24.46%	26.32%	24.46%	26.32%	26.32%	26.32%	26.32%

B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Remaining unresolved at the end of the quarter	Nil

Handwritten signatures and initials: A checkmark, 'BY', and a signature.

**CAMSON BIO TECHNOLOGIES LIMITED**  
**REPORT OF SEGMENT-WISE CONSOLIDATED REVENUE, RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR QUARTER AND YEAR ENDED AS ON 31ST MAR 2015**

Sl. No.	Particulars	Consolidated							
		Quarter Ended		Year Ended		Year Ended		Previous Year Ended	
		31st Mar 2015 (Audited)	31st Dec 2014 (Unaudited)	31st Mar 2015 (Audited)	31st Mar 2014 (Audited)	31st Mar 2015 (Audited)	31st Mar 2014 (Audited)	31st Mar 2014 (Audited)	31st Mar 2014 (Audited)
1	Segment Revenue								
	a) Seeds	5,923.96	4,206.48	3,163.51	14,153.83	14,734.68	14,754.86		
	b) Agribiotech Products	569.43	2,014.98	839.05	5,985.10	4,334.28	4,334.28		
	c) Others	57.18	129.69	-	186.87	-	-		
	Total	4,650.57	6,351.15	4,002.57	20,335.80	19,068.96	19,089.16		
	Less: Intersegment Revenue								
	Net Sales/ Income from Operation	4,650.57	6,351.15	4,002.57	20,335.80	19,068.96	19,089.16		
2	Segment Results								
	Profit (+) / Loss (-) before tax and interest from each segment:								
	a) Seeds	342.01	391.79	947.52	1,137.20	2,085.93	2,085.93		
	b) Agribiotech Products	(344.19)	284.25	(158.15)	511.96	432.42	432.42		
	c) Others	(16.63)	(21.50)	-	(38.13)	-	-		
	Total	(18.81)	654.54	789.37	1,611.03	2,518.35	2,518.35		
	Less: (i) Other Net unallocated income / expenses	338.28	217.77	-	993.23	861.76	861.76		
	(ii) Finance Cost	107.48	102.06	122.14	408.73	387.59	387.59		
	Total Profit before Tax	(484.57)	334.71	667.23	209.07	1,269.00	1,269.00		
3	Capital Employed								
	(Segment Assets - Segment Liabilities)								
	a) Seeds	14,153.15	13,305.60	15,907.38	14,153.15	15,907.38	15,907.38		
	b) Agri Biotech products	9,035.30	9,644.85	5,435.09	9,025.30	5,435.09	5,435.09		
	c) Others	3,144.19	3,348.95	1,395.34	3,144.19	1,395.34	1,395.34		
	TOTAL	26,332.64	26,302.40	22,737.81	26,332.64	22,737.81	22,737.81		

Rupees in Lakhs

**CAMSON BIO TECHNOLOGIES LIMITED**  
**STATEMENT OF ASSETS AND LIABILITIES UNDER CLAUSE 4(i)(v) OF THE LISTING AGREEMENT**

Sl. No	PARTICULARS	Consolidated		Rupees in Lakhs
		As at 31-Mar-15 (Audited)	As at 31-Mar-14 (Audited)	
<b>A</b>	<b>EQUITY AND LIABILITIES</b>			
1	Shareholders' Funds			
	(a) Share Capital	2,999.98	2,522.55	
	(b) Reserves and Surplus	23,324.65	17,804.22	
	(c) Money Received Against Share Warrants	-	2,311.04	
	Sub Total - Shareholders Funds	26,324.63	22,737.81	
	Minority Interest	292.69	26.49	
2	Non-Current Liabilities			
	(a) Long Term Borrowings	725.56	1,190.55	
	(b) Other Long term Liabilities	244.97	191.74	
	(c) Deferred Tax Liabilities (Net)	177.97	-	
	(d) Long Term Provisions	93.86	54.15	
	Sub Total - Non Current liabilities	1,538.05	1,440.44	
3	Current Liabilities			
	(a) Short Term Borrowings	3,840.63	2,512.38	
	(b) Trade Payables	2,055.91	1,102.24	
	(c) Other Current Liabilities	731.85	896.44	
	(d) Short Term Provisions	284.25	410.92	
	Sub Total - Current Liabilities	6,913.14	4,923.96	
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>34,772.82</b>	<b>29,128.72</b>	
<b>B</b>	<b>ASSETS</b>			
1	Non-Current Assets			
	(a) Fixed Assets			
	(i) Tangible Assets	12,417.65	7,755.76	
	(ii) Intangible Assets	2,919.41	3,405.69	
	(iii) work in progress	-	0.99	
	Intangible Asset under Development	0.95	-	
	Good will on consolidation	0.25	0.25	
	(b) Non-Current Investments	0.18	0.18	
	(c) Deferred Tax Asset (Net)	-	10.99	
	(d) Long Term Loans & Advances	174.17	4,081.35	
	Sub Total - Non-Current Assets	15,532.61	15,055.21	
2	Current Assets			
	(a) Inventories	2,797.10	4,041.49	
	(b) Trade Receivables	15,774.91	9,354.58	
	(c) Cash & Cash Equivalents	145.64	195.62	
	(d) Short Term Loans & Advances	542.56	483.82	
	(e) Other Current Assets	-	-	
	Sub Total - Current Assets	19,260.21	14,075.51	
	<b>TOTAL ASSETS</b>	<b>34,772.82</b>	<b>29,128.72</b>	

*(Handwritten signatures and initials)*

**CAMSON BIO TECHNOLOGIES LIMITED**

**Notes :**

- The above Financial Results were reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at its meeting held on 19th May 2015.
- The Company has opted to publish only audited standalone Financial Results. The audited consolidated Financial Results for the quarter and year ended Mar 31, 2015 of the Company will be available on the website of the Company and BSE.
- The nature of the company's business being related to agriculture and the composition of income varying due to the underlying environmental and market conditions, the results of the company quarter on quarter can vary significantly and are therefore not comparable.
- The Company has revised depreciation rates on fixed assets effective April 1, 2014 in accordance with requirement of schedule II of Companies Act 2013 ("the Act"). The remaining useful life has been revised by adopting standard useful life as per the Companies Act, 2013. Subsequent upon such change the depreciation amounting to Rs.90.78 lakhs (net of deferred tax of Rs. 8.91 lakhs) has been adjusted against reserves in respect of assets which have already completed their useful lives before April 2014 and for other assets depreciation has been charged based on their remaining useful life. Had the company continued with the previously assessed useful lives, the charge for depreciation would have been lower by Rs.93.77 and Rs.353 lakhs for the quarter and year ended 31st Mar 2015 respectively.
- "The Management of the Company intended to demerge its seeds division to Camson Seeds Limited through Court approved Scheme of Arrangement. In this process, the Management has conducted and obtained approval in the Court Convened Meetings of shareholders and creditors on April 23, 2015 and complied with the directions of High Court as per dated 26<sup>th</sup> March, 2015. The Company has filed the voting results and outcome of the meeting with Stock Exchange (BSE). The Company has filed the Petition vide no.105/2015 with Honbl. High Court of Karnataka and awaiting Approval". On approval of the Scheme by the Honourable High Court, shareholders of Camson Bio Technologies Limited will get one equity share of Camson Seeds Limited for every share held in Camson Bio Technologies Limited.

Financial results of discontinuing operation, subject to approval of the scheme by the Honourable High Court, under Accounting Standard 24 are given below : -

PARTICULARS	2014-15	2013-14
REVENUE	1,09,58,94,512	1,02,60,12,151
EMPLOYEE BENEFIT COST	3,51,57,256	2,91,03,899
DEPRECIATION	5,53,72,217	2,98,80,680
FINANCE COST	2,64,06,141	2,72,56,109
OTHER EXPENSES	28,45,24,958	16,22,98,560
NET PROFIT	13,94,79,190	11,88,51,644

- The Company has formulated Employee Stock Option plan 2012, drafted in accordance with the SEBI (Employee Stock Option Scheme) Guidelines, 1999. The Company has granted 14,99,990 stock options to their eligible employees in its board meeting held on Dt: Feb 12, 2015, to acquire equity shares of the Company which vest in a graded manner and to be exercised within a specified period. In accordance with the SEBI Guidelines: the excess of Rs. 0.50/- on the closing market price of Rs. 109.5/-, the day prior to the grant of the options under ESOS over the exercise price of Rs. 109/- is amortized on a straight-line basis over the vesting period. (Amortization amount - Rs. 32876/-)
- As per the Scheme, the Remuneration / Compensation Committee granted the options to the employees deemed eligible. The exercise price of each option is Rs 109. The Vesting period of the options shall be as follows:

After the date for Grant, upon the expiry of	% of options which would vest
12 months	33.34% of options
24 months	33.33% of options
36 months	33.33% of options

- The Company operates in two segments i.e. Seeds and Agribiotech products.
- The figures of last quarter are the balancing figures between audited figures in respect of full financial year and the published year to date figures upto third quarter of current financial year. A limited review was carried out on the figures for the quarter ended 31st December, 2014.
- Figures for the previous periods/years have been regrouped/rearranged wherever necessary.

Date : 19.05.2015  
Place: Bangalore

*(Handwritten initials)*



For and on behalf of the Board of Directors  
*(Handwritten signature)*  
DHIRENDRA KUMAR  
Managing Director





Stable revenue growth of 16.3% on a standalone basis;  
Driven by strong growth of 39.3% in the Agri-biotech business

Agri-biotech business at an inflexion point; to step into next orbit of  
growth from here

#### Standalone Performance Highlights

- Net Sales of Rs. 16,938 Lakhs, up 16.3% Y-o-Y
- EBITDA of Rs. 1,771 Lakhs
- Net Income of Rs. 308 Lakhs

#### Segment highlights

(Rs. lakhs)	FY2015	FY2014	Change %
Seeds	10,943.05	10,260.12	6.7%
Agri Biotech	5,995.10	4,302.66	39.3%

**Bangalore, India, May 19, 2015** – Camson Bio Technologies Limited, India's first integrated IPR driven agricultural biotechnology company, announces its financial results for FY2015. Standalone revenue during the full year FY2015 was Rs. 16,938 lakh representing a growth of 16.3% year-on-year. This was primarily driven by a robust 39.3% growth in the Agri-Biotech business while the Seeds business registered a modest 6.7% growth due to the ongoing portfolio rationalisation. Performance during the Q4 FY2014-15 was temporarily impacted by the non-seasonal rainfall during the last quarter. However, the company is bullish about the prospects of this segment which has the potential to bring about a meaningful change in agriculture.

#### Recent Corporate Developments:

- Received approval from Shareholders and Creditors for the Scheme of Arrangement (Demerger) of the Seeds Business to create a separate entity Camson Seeds Limited
- Signed MOU with the Kerala Cardamom Processing and Marketing Company to facilitate residue free farming for Kerala farmers
- Signed MOU with Vazhakkulam Pineapple Growers and Processors Pvt. Ltd. to advance the usage of biocide products in pineapple farming
- Signed MOU with the Coconut Development Board (a Government of India enterprise), to undertake research on secondary metabolite based biocides to control red palm weevil infesting coconut plantations





Commenting the business and performance, **Mr. Santosh Nair, CEO of Camson Biotechnologies Limited** said:

*“Last financial year has been an inflexion point for our core biocides business from where we expect to move to the next trajectory of growth. During the year, we made significant investments in our R&D, sales & marketing channels and overall human resources. We believe that these investments will fructify in the coming year. Although, the performance of the last quarter was impacted by unseasonal rains which resulted in subdued sales coupled increased sales & marketing expenses to push sales in bad weather conditions. This is a short term phenomenon and we have taken essential steps to minimise the impact.*

*In Q4 FY2015, we signed several MoUs with government organisations to undertake research on secondary metabolite based biocides for them. It gives me immense pleasure to see that our efforts to create a strong microbe research based, bio-technology driven organisation has been recognised at all levels. Our products have already created a brand recall for themselves and we have an exciting pipeline for the next year to build upon the existing portfolio. We look forward to an exciting phase of growth for the Company.”*

.....

**About Camson:**

Camson Bio Technologies Limited (“Camson” or the “Company”) is India's first integrated IPR driven agricultural biotechnology company. Founded in 1993, Camson is headquartered in Bangalore, with primary focus on biotech R&D. The Company is a pioneer in zero residue farming products, which uses secondary metabolites (biological origin) of microbes to kill / inhibit pathogens, with no use of chemicals. It has been recognized by Deloitte as one the fastest growing technology companies in 2015 and conferred the Technology Fast 500 award and awarded the Leaders of Tomorrow Award by ET Now & Indiamart 2014-15.

**Contact Details:**

Camson Bio Technologies Limited (CIN: L85110KA1993PLC014944), C-7, 7th Floor, Corporate Block, Golden Enclave, Old Airport Road, Bangalore - 560 017

B.S.K Sirish *info@camsonbiotechnologies.com*  
Company Secretary, Camson Bio Technologies Limited +91 80 4076 8900

Sumeet Chhabria *sumeet@camsonbiotechnologies.com*  
*Camson Bio Technologies* +91 80 4076 8900

Saket Somani *camson@churchgatepartnersindia.com*  
*Churchgate Partners* +91 22 3953 7444





**Safe Harbour:**

*This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Camson’s future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Camson undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances*

